Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue

Laboratory Investigation

Volumn 92, Issue 9, 2012, Pages 1342-1357

  Potts, Steven J ^a   Krueger, Joseph S ^a   Landis, Nicholas D ^a   Eberhard, David A ^b   David Young, G ^a   Schmechel, Steven C ^c   Lange, Holger ^a  

^a Flagship Biosciences   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

breast cancer; digital pathology; HER2; immunohistochemistry; pathology; tumor heterogeneity

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; CANCER TISSUE; COHORT ANALYSIS; CONTROLLED STUDY; GENETIC HETEROGENEITY; HAPLOTYPE MAP; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; PATHOLOGIST; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM;

BREAST NEOPLASMS; FEMALE; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; STAINING AND LABELING;

EID: 84865623584     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2012.91     Document Type: Article

References (31)

1. Esteva FJ, Yu D, Hung MC, et al. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol 2010;7: 98-107.
2. Wolff AC, Hammond ME, Schwartz JN, et al. American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18-43. (Pubitemid 46174133)
3. Weinhouse S. Discussion of Doctor Greenstein's paper. Cancer Res 1956;16:654-657.
4. Lewis JT, Ketterling RP, Halling KC, et al. Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining. Am J Clin Pathol 2005;124: 273-281. (Pubitemid 41060140)
5. Shin SJ, Hyjek E, Early E, et al. Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray. Int J Surg Pathol 2006;14:279-284. (Pubitemid 44545764)
6. Wu JM, Halushka MK, Argani P. Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer. Hum Pathol 2010;41:914-917.
7. Davila E, Amazon K. The clinical importance of the heterogeneity of HER2 neu. Case Rep Oncol 2010;3:268-271.
8. Polyak K, Shipitsin M, Campbell-Marrotta L, et al. Breast tumor heterogeneity: causes and consequences. Breast Cancer Res 2009;11: S1-S18.
9. Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 2010;1805:105-117.
10. D'Alfonso T, Liu YF, Monni S, et al. Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed. Am J Surg Pathol 2010;34:575-581.
11. Vance GH, Barry TS, Bloom KJ, et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med 2009;133:611-612.
12. Howard V, Reed MG. Unbiased Stereology, 2nd edn. Garland Science/BIOS Scientific Publishers: New York, 2004.
13. Shannon CE, Weaver W. The Mathematical Theory of Communication. University of Illinois Press: Urbana, IL, 1949.
14. Simpson EH. Measurement of diversity. Nature 1949;163:688.
15. Park SY, Gonen M, Kim HJ, et al. Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest 2010;120:636-644.
16. Rao CR. Diversity and dissimilarity coefficients: s unified approach. Theoret Popul Biol 1982;21:24-43.
17. Pavoine S, Dolédec S. The apportionment of quadratic entropy: a useful alternative for partitioning diversity in ecological data. Environ Ecol Stat 2005;12:125-138. (Pubitemid 40782273)
18. McCabe A, Dolled-Filhart M, Camp RL, et al. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 2005;97:1808-1815. (Pubitemid 43033901)
19. Ihaka RG, R. R: a language for data analysis and graphics. J Comp Graph Stat 1996;5:299-314.
20. Hameed O, Adams AL, Baker AC, et al. Using a higher cutoff for the percentage of HER2+ cells decreases interobserver variability in the interpretation of HER2 immunohistochemical analysis. Am J Clin Pathol 2008;130:425-427.
21. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006;24:3032-3038. (Pubitemid 46638937)
22. Theillet C. What do we learn from HER2-positive breast cancer genomic profiles? Breast Cancer Res 2010;12:107.
23. Esteva FJ, Guo H, Zhang S, et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 2010;177: 1647-1656.
24. Allison KH, Dintzis SM, Schmidt RA. Frequency of HER2 heterogeneity by fluorescence in situ hybridization according to CAP expert panel recommendations: time for a new look at how to report heterogeneity. Am J Clin Pathol 2011;136:864-871.
25. Bartlett AI, Starcyznski J, Robson T, et al. Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition. Am J Clin Pathol 2011;136:266-274.
26. Ohlschlegel C, Zahel K, Kradolfer D, et al. HER2 genetic heterogeneity in breast carcinoma. J Clin Pathol 2011;64:1112-1116.
27. Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 2001;23:291-299. (Pubitemid 32762920)
28. Glockner S, Buurman H, Kleeberger W, et al. Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer. Lab Invest 2002;82:1419-1426. (Pubitemid 35191545)
29. de Aretxabala X, Yonemura Y, Sugiyama K, et al. Gastric cancer heterogeneity. Cancer 1989;63:791-798. (Pubitemid 19050287)
30. Baldus SE, Schaefer KL, Engers R, et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010;16:790-799.
31. Grabsch H, Sivakumar S, Gray S, et al. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value\conclusions from 924 cases of two independent series. Cell Oncol 2010;32:57-65.